EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prostaglandin E 2 -EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth

Ryuma Matsuura, Siwakorn Punyawatthananukool, Ryoji Kawakami iD, Norihisa Mikami iD, Shimon Sakaguchi iD, Shuh Narumiya

Proceedings of the National Academy of Sciences · 09.12.2025 · 122 (49)

DOI: 10.1073/pnas.2424251122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 04.12.2025. Verfasst von Ryuma Matsuura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, EP4 Subtype, Dinoprostone, T-Lymphocytes, Regulatory, Receptors, Prostaglandin E, EP2 Subtype. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Foxp3 + regulatory T cells (Tregs) heavily infiltrate malignant tumors and restrict antitumor immunity. These tumor-infiltrating Tregs (TI-Tregs) adopt a distinct phenotype by expressing a unique set of genes. This TI-Treg gene expression signature is conserved in TI-Tregs across species and tumor types and stages, suggesting the presence of a common inducing mechanism in the tumor microenvironment (TME). However, identity of such a mechanism remains elusive. Here, we show that prostaglandin E 2 (PGE 2 ) produced in TME directly acts on its receptor EP2/EP4 on Tregs to induce the TI-Treg phenotype. PGE 2 added to TCR-activated Tregs induces a set of genes, many of which are included in the TI-Treg signature, in both induced Tregs (iTregs) and naturally occurring Tregs (nTregs) via EP2/EP4- cAMP-PKA pathway. Concomitantly, PGE 2 -treated Tregs exhibit potent suppressive activity to CD8 + T cells and strongly inhibit their proliferation in an EP4 dependent manner. Consistently, selective loss of EP2 and EP4 in mouse Tregs reduces expression of those genes in Tregs infiltrating Lewis lung carcinoma 1 (LLC1) mouse tumor and significantly delays the tumor progression. In human FOXP3 + iTregs, PGE 2 -EP4 signaling upregulated the expression of Treg signature genes, FOXP3, CD25, and CTLA-4 as well as a typical TI-Treg signature gene, 4-1BB, and enhanced suppressive activity. Furthermore, analysis of single-cell RNA sequencing of nasopharyngeal cancer patients demonstrates preferential expression of the TI-Treg signature genes in Tregs infiltrating the PTGS2 hi tumor group compared to the PTGS2 lo tumor group. These findings suggest that PGE 2 -EP2/EP4 signaling is one of the core mechanisms inducing the TI-Treg phenotype in TME for tumor growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Prostaglandin E, EP4 SubtypeDinoprostoneT-Lymphocytes, RegulatoryReceptors, Prostaglandin E, EP2 SubtypeLymphocytes, Tumor-InfiltratingAnimalsMiceSignal TransductionTumor MicroenvironmentHumansPhenotypeMice, Inbred C57BLCell Line, TumorFemale

Stichwörter der Autor:innen

EP4 receptorprostaglandin E2regulatory T cellstumor microenvironment

Substanzen

Receptors, Prostaglandin E, EP4 SubtypeDinoprostoneReceptors, Prostaglandin E, EP2 SubtypePtger4 protein, mouse

Autor:innen und Institutionen

  • Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
  • Department of Experimental Pathology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
  • Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
  • AMED-FORCE, Japan Agency for Medical Research and Development, Tokyo 100-0004, Japan.
  • Foundation for Biomedical Research and Innovation at Kobe, Kobe 650-0047, Japan.

ORCID-Profile: Ryoji Kawakami, Norihisa Mikami, Shimon Sakaguchi

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology (MEXT)
  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Matsuura, R., Punyawatthananukool, S., Kawakami, R., Mikami, N., Sakaguchi, S., & Narumiya, S. (2025). Prostaglandin E 2 -EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth. Proceedings of the National Academy of Sciences, 122(49). https://doi.org/10.1073/pnas.2424251122

Vancouver

Matsuura R, Punyawatthananukool S, Kawakami R, Mikami N, Sakaguchi S, Narumiya S. Prostaglandin E 2 -EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth. Proceedings of the National Academy of Sciences. 2025;122(49). doi:10.1073/pnas.2424251122

BibTeX
@article{Matsuura2025,
  author = {Matsuura, Ryuma and Punyawatthananukool, Siwakorn and Kawakami, Ryoji and Mikami, Norihisa and Sakaguchi, Shimon and Narumiya, Shuh},
  title = {Prostaglandin E 2 -EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {49},
  doi = {10.1073/pnas.2424251122}
}
Kostenlos starten →